Clinical trials: Respiratory Therapy
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
In this study, participants with programmed cell death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to 35 treatments or standard of care (SOC)…
- Trial name
- NCT02220894
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Volunteers
- 1,274 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00454194
- Testing
- pemetrexed disodium, sorafenib tosylate
- Where
- 207 sites in United States
- Volunteers
- 110 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
This single arm, open-label study will assess the efficacy and safety of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations.
- Trial name
- NCT01287754
- Testing
- erlotinib [Tarceva]
- Where
- 5 sites in Finland
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Seasonal Allergic Rhinitis
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Study P05106)(COMPLETED)
This study is designed to assess the effectiveness of mometasone furoate nasal spray (MFNS) once daily compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total symptom score.
- Trial name
- NCT00468312
- Testing
- Mometasone furoate nasal spray
- Volunteers
- 429 people
- Sponsor
- Organon and Co
Perennial Allergic Rhinitis
Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus…
- Trial name
- NCT01401465
- Testing
- ciclesonide, mometasone
- Where
- 15 sites in United States
- Volunteers
- 327 people
- Sponsor
- Sumitomo Pharma America, Inc.
Lung Cancer, Head and Neck Cancer
A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation
Approximately 60 patients will be enrolled with highly suspected lung cancer, or head and neck cancer. The patients must also be starting radiotherapy or a chemoradiotherapy regimen (except with 5-fluorouracil).
- Trial name
- FLT101 (NCT00847509)
- Testing
- [F-18]FLT
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Siemens Molecular Imaging
Asthma
Roflumilast Plus Montelukast in Adults With Severe Asthma
This study will evaluate the effect of roflumilast 500 μg once daily (QD) plus montelukast 10 mg QD versus 10 mg montelukast QD alone on predose (trough) prebronchodilator forced expiratory volume in the first second (FEV1).
- Trial name
- NCT01765192
- Testing
- Roflumilast, Montelukast
- Where
- 13 sites in Germany, Hungary and 1 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Asthma
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent asthma.
- Trial name
- NCT02105012
- Testing
- BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg
- Where
- 41 sites in United States
- Volunteers
- 147 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive, Asthma
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00452400
- Testing
- BI 1744CL
- Where
- 42 sites in United States, Canada and 2 more
- Volunteers
- 409 people
- Sponsor
- Boehringer Ingelheim
Chronic Graft Versus Host Disease
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant…
- Trial name
- NCT02491359
- Testing
- Carfilzomib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
COVID-19
BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of BRII-196/BRII-198 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780424
- Testing
- BRII-196, BRII-198, Remdesivir
- Where
- 107 sites in United States, Denmark and 6 more
- Volunteers
- 353 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Hypertension
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study was an international, multicenter, randomized (2:1 active:placebo), double-blind, placebo-controlled study in subjects with PAH who were NOT currently receiving approved therapy for their PAH.
- Trial name
- NCT00325403
- Testing
- Oral treprostinil (UT-15C) Sustained Release Tablets
- Where
- 77 sites in United States, Austria and 11 more
- Volunteers
- 349 people
- Sponsor
- United Therapeutics
Severe Pneumonia
Reparixin in COVID-19 Pneumonia - Efficacy and Safety
Phase 2 Study Objectives: efficacy and safety of of Reparixin treatment as compared to the control arm in adult patients with severe COVID-19 pneumonia Phase 3 Study Objectives: efficacy and safety of Reparixin treatment as…
- Trial name
- NCT04794803
- Testing
- Reparixin, Standard of care
- Where
- 4 sites in Brazil, Italy
- Volunteers
- 56 people
- Sponsor
- Dompé Farmaceutici S.p.A
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
- Trial name
- NCT03112603
- Testing
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX)
- Where
- 191 sites in United States, Australia and 29 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Asthma
A Long-term Safety Study of QVM149 in Japanese Patients With Asthma
The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.
- Trial name
- NCT03100825
- Testing
- QVM149
- Where
- 25 sites in Japan
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)
The purpose of this study is to determine if therapeutic dose anticoagulation (experimental group) improves 30-day mortality in participants with COVID-19 compared to those patients receiving the intermediate dose prophylaxis…
- Trial name
- IMPACT (NCT04406389)
- Testing
- Enoxaparin sodium, Unfractionated heparin, Fondapariniux
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Weill Medical College of Cornell University
Asthma
Utilizing CT Based Imaging Parameters of Body Composition to Understand Heterogeneity of Response to Biologic Therapies in Severe Asthma Cohorts
This study will utilize University of Michigan EMR data to form a retrospective cohort of severe asthma patients on biologic therapies for asthma with computed tomography (CT) imaging and known outcomes on therapy.
- Trial name
- NCT06922760
- Where
- 2 sites in United States
- Volunteers
- 233 people
- Sponsor
- University of Michigan
Non-small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery…
- Trial name
- NCT03425643
- Testing
- Pembrolizumab, Cisplatin, Gemcitabine
- Where
- 227 sites in United States, Argentina and 23 more
- Volunteers
- 797 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease
Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol
This study investigated the effect of exercise and high-dose salbutamol on the maximum heart rate in patients with chronic obstructive pulmonary disease (COPD) receiving therapeutic doses of indacaterol, salmeterol and placebo.
- Trial name
- NCT00531050
- Testing
- Indacaterol, Salmeterol
- Where
- Belgium
- Volunteers
- 27 people
- Sponsor
- Novartis
Small Cell Lung Cancer
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
The purpose of this study is to determine the efficacy of rovalpituzumab tesirine as a third-line and later treatment for participants with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer…
- Trial name
- TRINITY (NCT02674568)
- Testing
- Rovalpituzumab tesirine
- Volunteers
- 342 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.